WO1991016900A1 - Fucosyl transferases involved in adhesion molecule expression - Google Patents

Fucosyl transferases involved in adhesion molecule expression Download PDF

Info

Publication number
WO1991016900A1
WO1991016900A1 PCT/US1990/006198 US9006198W WO9116900A1 WO 1991016900 A1 WO1991016900 A1 WO 1991016900A1 US 9006198 W US9006198 W US 9006198W WO 9116900 A1 WO9116900 A1 WO 9116900A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
cdx
dna
dna sequence
clone
Prior art date
Application number
PCT/US1990/006198
Other languages
English (en)
French (fr)
Inventor
Susan E. Goelz
Roy R. Lobb
Catherine A. Hession
Original Assignee
Biogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1990/002357 external-priority patent/WO1990013300A1/en
Application filed by Biogen, Inc. filed Critical Biogen, Inc.
Priority to AU71693/91A priority Critical patent/AU648539B2/en
Publication of WO1991016900A1 publication Critical patent/WO1991016900A1/en
Priority to NO91915082A priority patent/NO915082L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/18—Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This invention relates to the biology of cell adhesion and, in particular, to molecules that are involved in the expression of surface ligands, particularly CDX, a glycoprotein involved in leukocyte binding to the adhesion molecule, ELAM1.
  • Inflammation characteristically involves, among other things, the adhesion of leukocytes (white blood cells) to the endothelial wall of blood vessels and the infiltration of leukocytes into the surrounding tissues. (Harlan, 1985.) In normal inflammation, the infiltrating leukocytes phagocytize invading organisms or dead cells and play a role in tissue repair. However, in pathologic inflammation, infiltrating leukocytes can cause serious and sometimes deadly damage.
  • ELAMl appears to be a major mediator of PMN adhesion to the inflamed vascular wall in vivo.
  • ELAMl is a 116 kD cell surface glycoprotein.
  • HUVECs human umbilical vein endothelial cells
  • HUVECs human umbilical vein endothelial cells
  • CDX is present on leukocyte cell types known to adhere to ELAMl and is absent from leukocyte cell types and other cell types that do not adhere to ELAMl.
  • CDX is a molecule expressed on certain leukocytes that plays an important role in ELAMl-mediated leukocyte- endothelial cell adhesion.
  • ELAMs may play important roles in a wide range of pathological states involving cell-cell recognition, including tumor invasion, metastasis and viral infection.
  • CDX and ELAMl play important roles in inflammation and, perhaps, other pathologies.
  • the isolation of molecules that contribute directly or indirectly to their expression will be an important step in the development of therapies aimed at preventing cell adhesion during inflammation or at limiting ELAMl and CDX involvement in other pathological states.
  • This invention provides DNA sequences encoding molecules that cause several cell lines, including COS, CHO and Rl.l, both to express surface glycoproteins that are recognized by anti-CDX ( ⁇ -CDX) antibodies and to bind to ELAMl.
  • This invention provides, in particular, clone 7.2 and clone 1, and protein 7.2 and protein 1, respectively. These proteins appear to be 1,3-fucosyl transferases.
  • This invention also provides the glycoproteins, Pseudo-X and Pseudo-X , which cause COS cells and CHO cells, respectively, to bind ELAMl and to be recognized by ⁇ :-CDX antibodies.
  • Figure 1 depicts the sequence of cDNA coding for protein 7.2 and the deduced amino acid sequence of protein 7.2 derived from pSQ219 and CDX pCDM8 clone 7.2.
  • the nucleotides are numbered 1-2175.
  • Figure 2 depicts the sequence of cDNA coding for protein 1 derived from clone 1.
  • the nucleotides are numbered 1-2861.
  • the coding DNA sequence of this figure as the DNA sequence for clone 1.
  • the polypeptide comprising the amino acid sequence depicted in this figure as protein 1.
  • Expression control sequence A DNA sequence that controls and regulates the transcription and translation of another DNA sequence.
  • a DNA sequence is operatively linked to an expression control sequence when the expression control sequence controls and regulates the transcription and translation of that DNA sequence.
  • the term "operatively linked” includes having an appropriate start signal (e.g., ATG) in front of the DNA sequence to be expressed and maintaining the correct reading frame to permit expression of the DNA sequence under the control of the expression control sequence and production of the desired product encoded by the DNA sequence. If a gene that one desires to insert into a recombinant DNA molecule does not contain an appropriate start signal, such a start signal can be inserted in front of the gene.
  • Standard hybridization conditions salt and temperature conditions substantially equivalent to 5 x SSC and 65°C for both hybridization and wash.
  • DNA sequences of this invention will hybridize to other DNA sequences having sufficient homology, including homologous sequences from different species. It is understood that the stringency of hybridization conditions is a factor in the degree of homology required for hybridization.
  • DNA sequences of this invention refer to DNA sequences prepared or isolated using recombinant DNA techniques. These include cDNA sequences, DNA sequences isolated from their native genome, and synthetic DNA sequences. The term as used in the claims is not intended to include naturally occurring DNA sequences as they exist in Nature. Expression of recombinant DNA molecules according to this invention may involve post- translational modification of a resultant polypeptide by the host cell. For example, in mammalian cells expression might include, among other things, glycosylation, lipidation or phosphorylation of a polypeptide, or cleavage of a signal sequence to produce a "mature" protein.
  • the term "protein” encompasses full-length polypeptides and modifications or derivatives thereof, such as glycosylated versions of such polypeptides, mature proteins, polypeptides retaining a signal peptide, truncated polypeptides having comparable biological activity, and the like.
  • the molecules of the present invention are involved in the expression of the glycoprotein, CDX, on the surface of certain leukocytes. CDX appears on SDS- PAGE as a single, diffuse band of about 150 kD. A 90 kD protein band was sometimes observed in the bound proteins from HL-60 cells and always in the proteins from neutrophils. We believe this 90 kD band represents a CDX degradation product.
  • 1,3-fucosyl transferases are highly specific enzymes that function in the Golgi apparatus and endoplasmic reticulum to attach fucosyl moieties to appropriate acceptor carbohydrates through a 1,3 glycosidic linkage. The genetic structure of these sequences is consistent with that of other, known glycosyl transferases.
  • CHO cells transfected with clone 7.2 express fucosyl transferase activity.
  • COS 7 cells When COS 7 cells were transfected with either of these two clones, they behaved like cells expressing CDX, that is, they became "visible" to ELAMl in that they were able to produce a surface glycoprotein to which ELAMl binds and which are recognized by the ⁇ -CDX monoclonal, SGB 3 B 4 .
  • ⁇ -CDX monoclonals we immunoprecipitated a 130 kD glycoprotein from transfected COS cells, which we have designated
  • Pseudo-X CHO cells transfected with clone 7.2 also became visible to ELAMl and ⁇ -CDX. They express a 140 kD glycoprotein which we have designated Pseudo-X . Neither Pseudo-X nor Pseudo-X are CDX.
  • Pseudo-X has a molecular weight of about 130 kD and Pseudo-X , of 140 kD.
  • CDX has a molecular weight of 150 kD.
  • N-glycanase or hydrofluoric acid which removes all carbohydrate
  • Pseudo-X shifts to 110 kD.
  • Pseudo-X shifts to approximately 120 kD.
  • CDX shifts to about 70 kD. Neither migrates at 46 kD or 59 kD, the predicted molecular weights of protein 7.2 and protein 1.
  • Pseudo-X and CDX also have different V8 and chymotrypsin digestion patterns.
  • DNA sequences disclosed herein may be expressed by operatively linking them to an expression control sequence in an appropriate expression vector and employing that expression vector to transform an appropriate unicellular host.
  • Such operative linking of a DNA sequence of this invention to an expression control sequence includes the provision of an initiation codon, ATG, in the correct reading frame upstream of the DNA sequence, if it is not already part of the DNA sequence or the expression vector.
  • Useful expression vectors may consist of segments of chromosomal, non-chromosomal and synthetic DNA sequences.
  • Suitable vectors include derivatives of SV40 and known bacterial plasmids, e.g., E.coli plasmids col El, pCRl, pBR322, pMB9 and their derivatives, plasmids such as RP4; phage DNAs, e.g., the numerous derivatives of phage ⁇ , e.g., NM989, and other phage DNA, e.g., M13 and Filamentous single stranded phage DNA; yeast plasmids such as the 2 ⁇ plasmid or derivatives thereof; vectors useful in eukaryotic cells, such as vectors useful in insect or mammalian cells; vectors derived from combinations of plasmids and phage DNAs, such as plasm
  • any of a wide variety of expression control sequences sequences that control the expression of a DNA sequence operatively linked to it — may be used in these vectors to express the DNA sequences of this invention.
  • useful expression control sequences include, for example, the early and late promoters of SV40 or adenovirus, the lac system, the trp system, the TAC or TRC system, the major operator and promoter regions of phage ⁇ , the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase or other glycolytic enzymes, the promoters of acid phosphatase (e.g., Pho5) , the promoters of the yeast ⁇ - mating factors, and other sequences known to control the expression of genes of prokaryotic or eukaryotic cells or their viruses, and various combinations thereof.
  • a wide variety of unicellular host cells are also useful in expressing the DNA sequences of this invention.
  • These hosts may include well known eukaryotic and prokaryotic hosts, such as strains of E.coli. Pseudomonas, Bacillus. Streptomyces. fungi such as yeasts, and animal cells, such as CHO, Rl.l, B-W and L-M cells, African Green Monkey kidney cells (e.g., COS 1, COS 7, BSC1, BSC40, and BMT10) , insect cells (e.g., Sf9) , and human cells and plant cells in tissue culture. It will be understood that not all vectors, expression control sequences and hosts will function equally well to express the DNA sequences of this invention.
  • Suitable expression control sequence a variety of factors will normally be considered. These include, for example, the relative strength of the system, its controllability, and its compatibility with the particular DNA sequence or gene to be expressed, particularly as regards potential secondary structures.
  • Suitable unicellular hosts will be selected by consideration of, e.g., their compatibility with the chosen vector, their secretion characteristics, their ability to fold proteins correctly, and their fermentation requirements, as well as the toxicity to the host of the product encoded by the DNA sequences to be expressed, and the ease of purification of the expression products. It will also be recognized that expression of the DNA sequences of the present invention may have different effects in different hosts.
  • clone 7.2 expressed in COS cells leads to the appearance of an ELAMl-binding surface molecule
  • expression of clone 7.2 in, e.g., prokaryotic host cells may have no similar effect, since prokaryotes lack internal cell structures (e.g., Golgi apparatus) that may be necessary for the biological functionality of protein 7.2.
  • prokaryotes lack internal cell structures (e.g., Golgi apparatus) that may be necessary for the biological functionality of protein 7.2.
  • host cells in which protein 7.2 does not have a function in the cellular biochemistry such as the catalytic role of a glycosyl transferase
  • the practitioner will be able to select the appropriate host cells and expression mechanisms for a particular purpose.
  • Several strategies are available for the isolation and purification of protein 7.2 and protein 1 after expression in a host system.
  • One method involves expressing the proteins in bacterial cells, lysing the cells, and purifying the protein by conventional means.
  • Colley et al. (1989) describe purifying a sialyltransferase by engineering the cleavable signal peptide of human gamma-interferon onto the DNA sequence for the transferase.
  • Larsen et al. (1990) fused the DNA sequence for protein A to the amino-terminal end of a fucosyl transferase gene and expressed it as an excreted fusion protein.
  • the 1,3-fucosyl transferases of this invention are useful for enzymatic synthesis of carbohydrates in vitro. Specifically, they are useful for catalyzing the linkage of fucose to appropriate acceptors through a 1,3 glycosidic bond.
  • suitable conditions for this catalysis in Example I, relating to an assay for fucosyl transferase activity.
  • One skilled in the art will recognize other suitable conditions under which the 1,3 fucosyl transferases described herein may be advantageously employed.
  • CDX is important in ELAMl-mediated cell adhesion.
  • a molecule comprising the carbohydrate moiety of CDX, Pseudo-X or Pseudo-X , or a fucose-containing portion of that moiety may be sufficient to function as an ELAMl ligand.
  • Such molecules may be useful in methods, including therapies, directed to inhibiting ELAM1- mediated cell adhesion.
  • This invention is also directed to small molecules that inhibit the activity of the 1,3-fucosyl transferases described herein, including synthetic organic chemicals, natural fermentation products, peptides, etc. These molecules may be useful in therapies aimed at inhibiting ELAMl-mediated cell adhesion.
  • a test mixture by contacting together an inhibitor candidate, a fucose acceptor and a 1,3-fucosyl transferase.
  • the fucose acceptor is, preferably,
  • the 1,3-fucosyl transferase preferably is derived from an extract from a cell transformed with clone 7.2 or clone 1. Then one assays the test mixture for 1,3-fucosyl transferase activity, such as described in Example I.
  • CDX clone 1 We isolated several long inserts from the HL-60 library, transfected them into COS 7 cells, and selected clones that bound to ELAMl and ⁇ -CDX. In this way we identified a 2.9 kb insert that could have come from the 3.0 kb message. We called it CDX clone 1.
  • the transfected COS cells also formed rosettes around Sepharose beads coated with recombinant soluble ELAMl (rsELAMl) ; and the rosetting was cation dependent and was inhibited by both BB11 (anti-ELAMl antibody) and ⁇ -CDX.
  • COS cells and CHO cells transfected with pCDM8 alone (without the inserted clone) did not rosette rsELAMl beads.
  • the COS and CHO cells transfected with clone 7.2 did not rosette to beads coated with bovine serum albumin.
  • Clone 1 encodes a polypeptide of 530 amino acids (encoded by nucleotides 174-1763 of Figure 2) .
  • Clone 7.2 encodes a 405-amino acid polypeptide (encoded by nucleotides 66-1280 in Figure 1) .
  • UWGCG Sequence Analysis Software Package version 6.1, Aug. 1989
  • NBRF Protein database release 23, Dec. 1989
  • FASTA FASTA for homology to other proteins.
  • GenBank release 63, Mar. 1990
  • EMBL release 19, May 1989
  • the portion of the nucleotide sequence of clone 7.2 from nucleotide 9 to nucleotide 2162 ( Figure 1) is identical to the portion of the sequence of clone 1 from nucleotide 492 to nucleotide 2645 ( Figure 2).
  • the first methionine of protein 7.2 corresponds to the methionine at amino acid 126 of protein 1.
  • the two inserts represent different transcripts from the same DNA segment. As we stated earlier, these clones do not code for CDX, Pseudo-X or Pseudo-X — the polypeptides they encode are not the correct size.
  • clone 7.2 and clone 1 encode 1,3-fucosyl transferases that glycosylate other proteins, such as CDX, Pseudo-X and Pseudo-X , in a way that makes them "visible” (i.e., recognized by or able to bind to) ELAMl or ⁇ -CDX.
  • DNA sequences of clone 1 and clone 7.2 share several structural features with the DNA sequences of known glycosyl transferases. For example, genes encoding known glycosyl transferases commonly have consecutive methionine start sites and are capable of producing more than one mRNA transcript.
  • clone 1 contains two codons that can serve as transcription start signals.
  • the clones have multiple SP1 enhancer sites. The nucleotide sequences for these sites are GGGCGG or CCGCCC; clone 1 has five such sites.
  • clones 7.2 and 1 are rich in guanine (G) and cytosine (C) . For example, clone 1 is 75% GC rich in the 5' region of the gene and 60% GC rich in the 3 ' region of the gene.
  • Glycosyl transferases in addition are typically class II membrane proteins, in which the membrane-spanning domain is near the amino terminus and the extracellular portion is near the carboxy terminus.
  • Clone 1 and clone 7.2 encode a polypeptide having a hydrophobic region near the amino terminus.
  • Glycosyl transferases also tend to have molecular weights between 40 kD to 60 kD; clone l encodes a polypeptide of about 59 kD and clone 7.2 encodes a polypeptide of about 46 kD.
  • known glycosyl transferases usually have one to three N-glycosylation sites; clone 1 and clone 7.2 both encode two such sites.
  • enzyme assays performed on extracts from CHO cells transfected with clone 7.2 revealed the presence of fucosyl transferases not expressed in untransformed cells.
  • the assays tested the ability of the enzyme to link radioactively labelled fucose to an acceptor molecule.
  • We prepared the enzyme by isolating about 1.5 million CHO cells transfected with clone 7.2 and lysing them by sonication for 15 seconds in 150 ⁇ l ice-cold 1% Triton X-100 in water.
  • the cocktail contained 75 ⁇ M 14 C-GDP fucose, 100 mM ATP, 500 mM L-fucose, 1 M MnCl and 1 M cacodylate at pH 6.2.
  • 10X acceptor contained, variously, 200 mM LacNAc, Lac-N-biose, or lactose, 250 mM phenyl-3-D-galactoside, or 50 mM 2 '-fucosyllactose.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Peptides Or Proteins (AREA)
PCT/US1990/006198 1990-04-27 1990-10-26 Fucosyl transferases involved in adhesion molecule expression WO1991016900A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU71693/91A AU648539B2 (en) 1990-04-27 1990-10-26 Fucosyl transferases involved in adhesion molecule expression
NO91915082A NO915082L (no) 1990-04-27 1991-12-23 Fucosyltransferaser involvert i adhesjonsmolekylekspresjon

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
USPCT/US90/02357 1990-04-27
PCT/US1990/002357 WO1990013300A1 (en) 1989-04-28 1990-04-27 ENDOTHELIAL CELL-LEUKOCYTE ADHESION MOLECULES (ELAMs) AND MOLECULES INVOLVED IN LEUKOCYTE ADHESION (MILAs)

Publications (1)

Publication Number Publication Date
WO1991016900A1 true WO1991016900A1 (en) 1991-11-14

Family

ID=22220826

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1990/006198 WO1991016900A1 (en) 1990-04-27 1990-10-26 Fucosyl transferases involved in adhesion molecule expression

Country Status (5)

Country Link
EP (1) EP0485532A1 (enrdf_load_stackoverflow)
JP (1) JPH05501359A (enrdf_load_stackoverflow)
AU (1) AU648539B2 (enrdf_load_stackoverflow)
NO (1) NO915082L (enrdf_load_stackoverflow)
WO (1) WO1991016900A1 (enrdf_load_stackoverflow)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2677040A1 (fr) * 1991-05-31 1992-12-04 Ciba Geigy Ag Procede pour la production de glycosyltransferases, vecteur hybride et souches de levures utilises a cette fin.
GR920100250A (el) * 1991-05-31 1993-03-31 Ciba Geigy Ag Βελτιωμένη μέ?οδος για την παραγωγή γλυκοσυλοτρανσφεράσης.
EP0640129A4 (en) * 1990-11-23 1994-07-05 Gen Hospital Corp Inhibition of cell adhesion protein-carbohydrate interactions.
US5641668A (en) * 1992-11-27 1997-06-24 Ciba-Geigy Corporation Proteins having glycosyltransferase activity
US5643873A (en) * 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
US5646123A (en) * 1991-06-10 1997-07-08 Alberta Research Council Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
US5648458A (en) * 1992-05-06 1997-07-15 Affymax Technologies N.V. Peptides and compounds that bind to ELAM-1
US5728802A (en) * 1992-05-06 1998-03-17 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
US5807745A (en) * 1991-03-11 1998-09-15 New England Medical Center Hospitals, Inc. Method of inhibiting PADGEM-mediated or ELAM-1-mediated leukocyte adhesion using an inhibitor comprising a Lex core component
US5856300A (en) * 1994-05-12 1999-01-05 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US5976540A (en) * 1993-05-17 1999-11-02 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US6096722A (en) * 1990-08-14 2000-08-01 Isis Pharmaceuticals Inc. Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
US6193979B1 (en) 1993-05-17 2001-02-27 Avant Immunotherapeutics, Inc. Compositions comprising complement receptor type 1 molecules having carbohydrate structures that are selectin ligands
US9234169B2 (en) 2008-07-16 2016-01-12 Glykos Finland Enzymatical modification of cell glycosylation using serum albumin and divalent cations
US9382512B2 (en) 2005-07-08 2016-07-05 Glykos Finland Oy Method for evaluating cell populations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272263A (en) * 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
CA2075949A1 (en) * 1990-02-14 1991-08-15 John B. Lowe Methods and products for the synthesis of oligosaccharide structures on glycoproteins, glycolipids, or as free molecules

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Cell, Vol. 63, No. 3, issued 02 November 1990, J.B. LOWE et al., "ELAM-1 dependent cell adhesion to a vascular endothelium determined by a transfected human fucosyltransferase cDNA", pages 475-484. See summary. *
See also references of EP0485532A4 *
The Journal of Biological Chemistry, Vol. 264, No. 29, issued 15 October 1989, M.M. PALCIC et al., "A Bisubstrate Analoge Inhibitor for alfa(1-2)-Fucosyltransferase", pages 17174-17181. See page 17174 cols. 1 and 2; page 17177, col. 2; and page 17178, col. 2. *
The Journal of Biological Chemistry, Vol. 264, No. 30, issued 25 October 1989, J.C. PAULSON et al., "Glyco syltransferases". See Table I and pages 17618, second full paragraph. *
The Journal of Biological Chemistry. Vol. 265, No. 3, issued 25 January 1990, B. POTVIN et al, Transfection of a Human alfa-(1,3) Fucosyltransferase Gene into Chinese Hamster Ovary Cells, pages 1615-1622. See Abstract; paragraph spanning cols. 1 and 2 of page 1615: and page 1616, col. 2, last full par. *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096722A (en) * 1990-08-14 2000-08-01 Isis Pharmaceuticals Inc. Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
EP0640129A4 (en) * 1990-11-23 1994-07-05 Gen Hospital Corp Inhibition of cell adhesion protein-carbohydrate interactions.
US6613746B1 (en) 1990-11-23 2003-09-02 The General Hospital Corporation AGP-antibody fusion proteins and related molecules and methods
US6156881A (en) * 1990-11-23 2000-12-05 The General Hospital Corporation Inhibition of cell adhesion protein-carbohydrate interactions
US5723583A (en) * 1990-11-23 1998-03-03 The General Hospital Corporation Antibody containing sialyl lewis X determinants
US5858983A (en) * 1990-11-23 1999-01-12 The General Hospital Corporation Inhibition of cell adhesion protein-carbohydrate interactions
US5801044A (en) * 1990-11-23 1998-09-01 The General Hospital Corporation Nucleic acid encoding an antibody that inhibits cell adhesion protein-carbohydrate interactions
US5807745A (en) * 1991-03-11 1998-09-15 New England Medical Center Hospitals, Inc. Method of inhibiting PADGEM-mediated or ELAM-1-mediated leukocyte adhesion using an inhibitor comprising a Lex core component
GR920100250A (el) * 1991-05-31 1993-03-31 Ciba Geigy Ag Βελτιωμένη μέ?οδος για την παραγωγή γλυκοσυλοτρανσφεράσης.
BE1005579A5 (fr) * 1991-05-31 1993-11-09 Ciba Geigy Procede pour la production de glycosyltransferases, vecteur hybride et souches de levures utilises a cette fin.
FR2677040A1 (fr) * 1991-05-31 1992-12-04 Ciba Geigy Ag Procede pour la production de glycosyltransferases, vecteur hybride et souches de levures utilises a cette fin.
US5646123A (en) * 1991-06-10 1997-07-08 Alberta Research Council Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
US5786322A (en) * 1992-05-06 1998-07-28 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1
US5728802A (en) * 1992-05-06 1998-03-17 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
US5648458A (en) * 1992-05-06 1997-07-15 Affymax Technologies N.V. Peptides and compounds that bind to ELAM-1
US5643873A (en) * 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
US5641668A (en) * 1992-11-27 1997-06-24 Ciba-Geigy Corporation Proteins having glycosyltransferase activity
US5976540A (en) * 1993-05-17 1999-11-02 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US6193979B1 (en) 1993-05-17 2001-02-27 Avant Immunotherapeutics, Inc. Compositions comprising complement receptor type 1 molecules having carbohydrate structures that are selectin ligands
US5856300A (en) * 1994-05-12 1999-01-05 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US9382512B2 (en) 2005-07-08 2016-07-05 Glykos Finland Oy Method for evaluating cell populations
US10000734B2 (en) 2005-07-08 2018-06-19 Glykos Finland Oy Method for evaluating cell populations
US9234169B2 (en) 2008-07-16 2016-01-12 Glykos Finland Enzymatical modification of cell glycosylation using serum albumin and divalent cations

Also Published As

Publication number Publication date
EP0485532A1 (en) 1992-05-20
AU7169391A (en) 1991-11-27
NO915082L (no) 1992-02-27
NO915082D0 (no) 1991-12-23
AU648539B2 (en) 1994-04-28
JPH05501359A (ja) 1993-03-18
EP0485532A4 (enrdf_load_stackoverflow) 1994-04-27

Similar Documents

Publication Publication Date Title
CA2063244A1 (en) Fucosyl transferases involved in adhesion molecule expression
Bierhuizen et al. Expression cloning of a cDNA encoding UDP-GlcNAc: Gal beta 1-3-GalNAc-R (GlcNAc to GalNAc) beta 1-6GlcNAc transferase by gene transfer into CHO cells expressing polyoma large tumor antigen.
AU731261B2 (en) Murine alpha(1,3)fucosyltransferase Fuc-TVII, DNA encoding the same, method for preparing the same, antibodies recognizing the same, immunoassays for detecting the same, plasmids containing such DNA, and cells containing such plasmid
US5858752A (en) Fucosyltransferase genes and uses thereof
AU648539B2 (en) Fucosyl transferases involved in adhesion molecule expression
AU706747B2 (en) Antibody specific for beta1->6N- acetylglucosamininyltransferase
US20060246468A1 (en) Alpha-1,3-fucosyltransferase
WO1997032889A9 (en) MURINE α(1,3)FUCOSYLTRANSFERASE Fuc-TVII, DNA ENCODING THE SAME, METHOD FOR PREPARING THE SAME, ANTIBODIES RECOGNIZING THE SAME, IMMUNOASSAYS FOR DETECTING THE SAME, PLASMIDS CONTAINING SUCH DNA, AND CELLS CONTAINING SUCH A PLASMID
US7935792B2 (en) Antibody reacting with N-acetylglucosamine-6-O-sulfotransferase product
CA2097617A1 (en) Inhibition of cell adhesion protein-carbohydrate interactions
CA2075949A1 (en) Methods and products for the synthesis of oligosaccharide structures on glycoproteins, glycolipids, or as free molecules
CA2114631C (en) N-acetylglucosaminyltransferase v coding sequences
US7399847B1 (en) Nucleic acids encoding artificial P-selectin ligands
US5691180A (en) DNA sequence encoding N-acetyl-galactosamine-transferase
US6670135B1 (en) Semaphorin polypeptides
CA2247966C (en) Murine .alpha.(1,3)fucosyltransferase fuc-tvii, dna encoding the same and uses thereof
JP3219585B2 (ja) 新規糖鎖合成酵素
JPH07327678A (ja) α２，８ シアリルトランスフェラーゼをコードするｃＤＮＡ

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP KR NO

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 2063244

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1991902457

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1991902457

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1991902457

Country of ref document: EP